Crispr Therapeutics AG (CRSP) Financials
$51.72
As on 11-Sep-2026 16:22EDT
Market cap
$5,001 Mln
Revenue (TTM)
$13 Mln
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-345.01
|
-142.77
|
-260.38
|
-495.74
|
538.97
|
|||||
|
Cash Flow from Investing Activities
|
--
|
-31.81
|
-280.48
|
374.65
|
-258.66
|
-1,035.43
|
|||||
|
Cash from Financing Activities
|
--
|
426.03
|
331.98
|
62.66
|
38.59
|
250.95
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
-715.80
|
-245.51
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-4.84
|
-6.47
|
-4.29
|
-1.89
|
-8.30
|
4.93
|
|||||
|
Cash EPS ($)
|
--
|
-6.25
|
-4.06
|
-1.64
|
-7.99
|
5.16
|
|||||
|
Adjusted Book Value ($)
|
--
|
21.37
|
22.61
|
23.15
|
23.94
|
31.30
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-3.84
|
-1.67
|
-3.20
|
-6.33
|
7.03
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-3.85
|
-1.69
|
-3.32
|
-6.80
|
5.97
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-26.01
|
-17.13
|
-7.24
|
-27.41
|
17.36
|
|||||
|
ROE (%)
|
-24.60
|
-30.18
|
-19.20
|
-8.17
|
-30.42
|
18.59
|
|||||
|
ROA (%)
|
-18.35
|
-25.81
|
-16.38
|
-6.87
|
-26.03
|
16.49
|
|||||
|
EBIT Margin (%)
|
-3,529.79
|
-16,466.24
|
-1,036.19
|
-40.74
|
-154,394.72
|
40.91
|
|||||
|
Net Margin (%)
|
-3,368.72
|
-16,569.77
|
-1,046.43
|
-41.52
|
-2,814.98
|
41.09
|
|||||
|
Cash Profit Margin (%)
|
0.00
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-64.15
|
-0.90
|
-0.91
|
847.62
|
-1.00
|
1,268.93
|
|||||
|
EBIT Growth (%)
|
-1.92
|
-59.37
|
-140.62
|
77.61
|
-280.22
|
205.39
|
|||||
|
Net Profit Growth (%)
|
3.56
|
-58.80
|
-138.43
|
76.37
|
-272.16
|
208.25
|
|||||
|
EPS Growth (%)
|
10.70
|
-0.51
|
-1.27
|
0.77
|
-2.68
|
1.99
|
|||||
|
Book Value Growth (%)
|
-7.92
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-8.11
|
-9.18
|
-33.14
|
-4.90
|
15.38
|
|||||
|
Price / Book Value
|
2.89
|
2.45
|
1.74
|
2.70
|
1.70
|
2.42
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
14.16
|
-5.60
|
-4.90
|
-27.78
|
-2.49
|
9.33
|
|||||
|
Close Price ($)
|
54.54
|
52.44
|
39.36
|
62.60
|
40.65
|
75.78
|
|||||
|
High Price ($)
|
78.48
|
78.48
|
91.10
|
76.97
|
86.95
|
220.20
|
|||||
|
Low Price ($)
|
44.12
|
30.04
|
38.20
|
37.55
|
38.94
|
67.15
|
|||||
|
Market Cap ($ Cr)
|
5,000.94
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
0.34
|
0.21
|
0.12
|
0.13
|
0.13
|
0.09
|
|||||
|
Short term debt to equity ratio
|
0.01
|
0.01
|
0.01
|
0.01
|
0.01
|
0.01
|
|||||
|
Current Ratio
|
17.85
|
13.32
|
22.07
|
17.54
|
15.30
|
20.17
|
|||||
|
Quick Ratio
|
17.85
|
--
|
--
|
--
|
15.39
|
--
|
|||||
|
Interest Coverage
|
--
|
--
|
--
|
--
|
-14.37
|
15.59
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
71.43
|
54.05
|
2,568.81
|
0.03
|
|||||
|
Asset Turnover
|
0.01
|
0.00
|
0.02
|
0.17
|
0.00
|
0.40
|
|||||
|
Receivable days
|
--
|
1,300.75
|
1,174.02
|
104.24
|
4,819.04
|
2.23
|
|||||
|
Inventory Days
|
--
|
--
|
--
|
-31.41
|
-37.10
|
--
|
|||||
|
Payable days
|
--
|
20.26
|
87.55
|
91.94
|
69.98
|
43.16
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
-19.11
|
4,711.96
|
--
|